阿利吉仑被证明会增加糖尿病患者的不良事件并伴随肾素-血管紧张素阻断。我们的目的是研究阿利吉仑在糖尿病和心血管风险增加或已建立心血管疾病患者中的疗效和安全性。
搜索MEDLINE和Embase的前瞻性研究,比较糖尿病和心血管疾病患者在标准药物治疗中添加阿利吉仑,或1个额外的心血管危险因素(高血压,血脂异常,微量白蛋白尿/蛋白尿,慢性肾脏疾病)。疗效的相对风险(全因死亡率,综合心血管死亡率和住院率)和安全性(高钾血症,低血压,计算肾损害)结局。
在搜索中确定的2151项研究中,7项研究纳入13,395例患者.阿利吉仑对全因死亡率没有影响(相对风险:1.05,95%置信区间:0.90至1.24,p=0.53),或合并心血管死亡率或心力衰竭住院(相对风险:1.07,95%置信区间:0.81至1.40,p=0.64)。接受阿利吉仑的患者发生高钾血症的风险更大(相对风险:1.32,95%置信区间:1.14至1.53,p=0.0003)和肾损害(相对风险:1.15,95%置信区间:1.02至1.30,p=0.03),但不是低血压.
患有糖尿病和心血管疾病或心血管风险的患者不会从标准药物治疗中添加阿利吉仑中获益。汇总分析中的有害安全性配置文件支持当前警告。
Aliskiren was shown to increase adverse events in patients with diabetes and concomitant renin-angiotensin blockade. We aim to investigate the efficacy and safety of
aliskiren in patients with diabetes and increased cardiovascular risk or established cardiovascular disease.
MEDLINE and Embase were searched for prospective studies comparing addition of
aliskiren to standard medical therapy in patients with diabetes and cardiovascular disease, or ⩾1 additional cardiovascular risk factor (hypertension, abnormal lipid profile, microalbuminuria/proteinuria, chronic kidney disease). Relative risk for efficacy (all-cause mortality, combined cardiovascular mortality and hospitalisation) and safety (hyperkalaemia, hypotension, renal impairment) outcomes was calculated.
Of 2151 studies identified in the search, seven studies enrolling 13,395 patients were included.
Aliskiren had no effect on all-cause mortality (relative risk: 1.05, 95% confidence interval: 0.90 to 1.24, p = 0.53), or combined cardiovascular mortality or heart failure hospitalisation (relative risk: 1.07, 95% confidence interval: 0.81 to 1.40, p = 0.64). Patients receiving
aliskiren had a greater risk of developing hyperkalaemia (relative risk: 1.32, 95% confidence interval: 1.14 to 1.53, p = 0.0003) and renal impairment (relative risk: 1.15, 95% confidence interval: 1.02 to 1.30, p = 0.03), but not hypotension.
Patients with diabetes and cardiovascular disease or cardiovascular risk do not benefit from the addition of aliskiren to standard medical therapy. Detrimental safety profile in pooled analysis supports current warnings.